A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

drug protocol number
R092670SCH3015
drug sponsor
anssen-Cilag International NV
drug study
paliperidone
drug trial site
JPH
drug status
Completed
drug phase